首页 | 本学科首页   官方微博 | 高级检索  
   检索      

前列腺癌患者组织中RPL6的表达及临床意义
引用本文:孙铭强,张建勇,袁 瑛,姚 成,敬秀清.前列腺癌患者组织中RPL6的表达及临床意义[J].现代生物医学进展,2018(4):745-749.
作者姓名:孙铭强  张建勇  袁 瑛  姚 成  敬秀清
作者单位:广元市第一人民医院肿瘤血液科;
摘    要:目的:探讨前列腺癌患者组织中核糖体蛋白L6(RPL6)表达,分析其对肿瘤恶性程度的评估作用。方法:收集2013年12月-2015年12月在本院接受治疗的前列腺疾病患者117例,根据病理结果分为前列腺炎组63例、前列腺癌组54例;另取同期进行健康体检的健康者80例作为正常对照组。采用Western-blot法检测三组研究对象的前列腺组织RPL6表达,采用酶联免疫吸附法(ELISA)测定血清肿瘤标志物含量,采用RT-PCR法检测前列腺组织增殖基因、侵袭基因mRNA表达,采用Pearson检验分析RPL6表达量与肿瘤恶性程度的相关关系。结果:前列腺癌组患者的前列腺组织RPL6表达量高于前列腺炎组及正常对照组(P0.05);前列腺癌组患者的血清前列腺特异性抗原(PSA)、前列腺特异性酸性磷酶(PSAP)、尿激酶型纤溶酶原激活剂(u PA)、硫氧还蛋白(TRX)含量高于前列腺炎组及正常对照组(P0.05);前列腺癌组患者的前列腺组织增殖基因URG11、PTEN mRNA表达量高于前列腺炎组及正常对照组,PRDM5 mRNA表达量低于前列腺炎组及正常对照组,侵袭基因IgGHG1、TMPRSS2-ER、PIK3C2B mRNA表达量高于前列腺炎组及正常对照组(P0.05)。前列腺癌患者的组织RPL6表达量与肿瘤标志物含量、增殖及侵袭基因活性均呈直接相关关系(P0.05)。结论:高表达的RPL6是前列腺癌早期诊断的可靠指标,且与肿瘤恶性程度直接相关,有望成为前列腺癌辅助诊断及预后评估的重要手段。

关 键 词:前列腺癌  核糖体蛋白L6  肿瘤标志物  增殖基因  侵袭基因
收稿时间:2017/4/29 0:00:00
修稿时间:2017/5/23 0:00:00

Prostate Cancer: Expression and Clinical Significance of Ribosomal Protein L6
Abstract:ABSTRACT Objective: To study the expression of Ribosomal protein L6(RPL6) in the tissues of patients with prostate cancer,and to evaluate the role of the protein in the grade malignancy. Methods: A total of 117 patients with prostate disease, who were treated in First People''s Hospital of Guangyuan from December 2013 to December 2015, were selected and divided into prostatitis group (n=63) and prostate cancer group(n=54) according to pathological results; in addition, 80 healthy people who underwent physical examination at the same time were enrolled as normal control group. The expression of RPL6 in the prostate tissue of three groups was detected by Western-blot. Serum tumor markers were detected by Enzyme-linked immunosorbent assay (ELISA). The levels of mRNA expression of proliferation gene and invasion gene were tested by RT-PCR. The relationship between RPL6 expression and malignant degree was analyzed by Pearson test. Results: The levels of RPL6 expression of prostate tissues in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). The serum contents of prostate specific antigen (PSA), prostatic acid phosphatase (PSAP), urokinase-type plasminogen activator (uPA), and thioredoxin (TRX) in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). The proliferation genes in the prostate tissues such as URG11 and PTEN mRNA in the prostate cancer group were higher than those in the prostatitis group and normal control group; PRDM5 mRNA expression in the prostate cancer group was lower than that in the prostatitis group and normal control group; the levels of invasion gene expression such as IgGHG1, TMPRSS2-ER, and PIK3C2B mRNA in the prostate cancer group were higher than those in the prostatitis group and normal control group (P<0.05). RPL6 expression in the tissues of prostate cancer patients was directly related to the content of tumor markers, proliferation and invasion genes (P<0.05). Conclusion: High expression of RPL6 is a reliable index for early diagnosis of prostate cancer, and it is directly related to the degree of malignancy, which is expected to be an important tool for the diagnosis and prognosis of prostate cancer.
Keywords:Prostate cancer  Ribosomal protein L6  Tumor marker  Proliferation Gene  Invasion Gene
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号